— Research library
We publish a monograph for every peptide in the catalog.
Mechanism, half-life, dose-response, known contraindications — and any study we chose to exclude from our summary, and why. If the evidence is thin, we say so.
— Monographs · Indexed
27 peptides, 412 indexed citations.
§01
BPC-157
Repair & GI integrity
42 studies · RCT limited
Open ↗
§02
TB-500
Actin-regulating repair
31 studies · Pre-clinical
Open ↗
§03
CJC-1295 / Ipamorelin
GH axis · Pulsatile
54 studies · Human data
Open ↗
§04
Tesamorelin
GHRH · Metabolic
89 studies · FDA approved
Open ↗
§05
Semaglutide
GLP-1 · Metabolic
140+ studies · FDA approved
Open ↗
§06
Tirzepatide
GLP-1 / GIP dual
118 studies · FDA approved
Open ↗
§07
Epithalon
Telomerase / circadian
29 studies · Ltd. clinical
Open ↗
§08
GHK-Cu
Copper tripeptide · Skin
46 studies
Open ↗
§09
Thymosin α-1
Immune modulation
77 studies · Human data
Open ↗
§10
NAD+
Mitochondrial coenzyme
60 studies
Open ↗
§11
Semax / Selank
Neuropeptide · Intranasal
38 studies · Primarily RU
Open ↗
§12
PT-141
Melanocortin · Libido
24 studies · FDA approved
Open ↗
§13
Kisspeptin
GnRH / LH modulation
52 studies · Human data
Open ↗
— How we test
Every lot passes three independent assays.
Assay · 01
HPLC purity
Reverse-phase high-performance liquid chromatography confirms ≥ 99% peptide purity. We reject lots below threshold, even when within industry spec.
Assay · 02
Mass spectrometry
MALDI-TOF confirms molecular weight matches the theoretical mass of the specified sequence within tolerance. This is identity verification, not just purity.
Assay · 03
Endotoxin (LAL)
Limulus amoebocyte lysate test for bacterial endotoxin burden. We require < 0.5 EU per mg of peptide — well below USP injectable threshold.
— Begin